CytoMed Therapeutics Limited Ordinary Shares (GDTC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

CytoMed Therapeutics Limited Ordinary Shares (GDTC) is down 19.1% since the beginning of the year. At $1 per share, GDTC is trading 70.7% below its 52-week high of $4.

CytoMed Therapeutics Limited Ordinary Shares (GDTC) has returned -19.10% so far this year and -52.63% over the past 12 months.

Based on dividend-adjusted daily data since Apr 14, 2023, GDTC's average daily return is 0.00%, while the average monthly return is -1.02%.

Historically, 41% of months were positive and 59% were negative. The best month was Oct 2024 with a return of +53.5%, while the worst month was Feb 2024 at -43.2%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 3 months.

On a daily basis, GDTC closed higher 44% of trading days. The best single day was Jul 11, 2023 with a return of +61.6%, while the worst single day was Feb 7, 2024 at -31.4%.

CytoMed Therapeutics Limited Ordinary Shares has an annualized alpha of -8.89%, beta of 0.52, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since April 14, 2023.

• This stock tended to rise when S&P 500 Index fell (downside capture of -133.73%), but participation in market rallies was also limited (-100.83%) - a profile typical of counter-cyclical assets.
• Beta of 0.52 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

GDTC ranks 17 for risk / return — in the bottom 17% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the CytoMed Therapeutics Limited Ordinary Shares. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the CytoMed Therapeutics Limited Ordinary Shares was 87.18%, occurring on May 7, 2026. The portfolio has not yet recovered.

The current CytoMed Therapeutics Limited Ordinary Shares drawdown is 80.85%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of CytoMed Therapeutics Limited Ordinary Shares over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how CytoMed Therapeutics Limited Ordinary Shares is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.